ARTICLE | Company News
Emergent BioSolutions, Oxford BioMedica deal
August 23, 2010 7:00 AM UTC
Emergent's Emergent Product Development Germany GmbH subsidiary received a non-exclusive, worldwide license to Oxford BioMedica's Hi-8 PrimeBoost technology and a sub-license to develop and commercialize vaccines and therapeutics using Oxford's poxvirus patents for eight infectious diseases, including tuberculosis. Oxford BioMedica received rights to the pox patents from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) in 2009. ...